Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BeOne Medicines's share price for the quarter that ended in Mar. 2026 was MXN2858.16. BeOne Medicines's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 111 Mil. Therefore, BeOne Medicines's market cap for the quarter that ended in Mar. 2026 was MXN317,716 Mil.
BeOne Medicines's quarterly market cap
increased
from Sep. 2025 (MXN316,175 Mil) to Dec. 2025 (MXN316,833 Mil) and
increased
from Dec. 2025 (MXN316,833 Mil) to Mar. 2026 (MXN317,716 Mil).
BeOne Medicines's annual market cap
declined
from Dec. 2023 (MXN402,247 Mil) to Dec. 2024 (MXN304,468 Mil) but then
increased
from Dec. 2024 (MXN304,468 Mil) to Dec. 2025 (MXN316,833 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BeOne Medicines's Enterprise Value for Today is MXN233,654 Mil.
BeOne Medicines (MEX:BGNEN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BeOne Medicines Market Cap Related Terms
BeOne Medicines Market Cap Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BGNEN vs RVMD, RPRX, BNTX: Market Cap Comparison
For the Biotechnology subindustry, BeOne Medicines's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Market Cap distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BeOne Medicines's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (MEX:BGNEN) has a Market Cap of MXN296,534 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #9 out of 1431 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is BeOne Medicines' Market Cap too high?
BeOne Medicines' current Market Cap is MXN296,534 Mil. Based on the distribution chart, BeOne Medicines ranks #9 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Market Cap compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #9 out of 1431 companies for Market Cap. This places BeOne Medicines in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Market Cap is MXN296,534 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Market Cap of MXN296,534 Mil. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Market Cap is MXN296,534 Mil. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Market Cap is MXN296,534 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.
Key valuation signals for MEX:BGNEN:
Market Cap: MXN296,534 Mil
GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for MEX:BGNEN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BGNEN has been successfully added to your 
